NASDAQ:AMRS - Amyris Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$7.52 -0.02 (-0.27 %)
(As of 10/22/2018 01:24 PM ET)
Previous Close$7.54
Today's Range$7.47 - $7.58
52-Week Range$2.82 - $9.28
Volume297,202 shs
Average Volume1.21 million shs
Market Capitalization$482.92 million
P/E Ratio-2.47
Dividend YieldN/A
Beta0.26
Amyris, Inc. provides various alternatives to a range of petroleum-sourced products worldwide. The company uses its industrial bioscience technology to design microbes primarily yeast, as well as to convert plant-sourced sugars into renewable ingredients. It produces and sells Biofene that converts to squalane, which is used as an emollient in cosmetics and other personal care products; and natural oils and aroma chemicals for the flavors and fragrances market. The company also provides renewable solvents, polymers, and lubricants for industrial markets; Biofene ingredients for nutraceuticals and vitamins market; and renewable fuels for transportation fuels markets. It has a collaboration partnership with Total S.A. to produce and commercialize Biofene-based diesel and jet fuels. The company was formerly known as Amyris Biotechnologies, Inc. and changed its name to Amyris, Inc. in June 2010. Amyris, Inc. was founded in 2003 and is headquartered in Emeryville, California.

Receive AMRS News and Ratings via Email

Sign-up to receive the latest news and ratings for AMRS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Industrial organic chemicals
Sub-IndustryOil & Gas Refining & Marketing
SectorBasic Materials
SymbolNASDAQ:AMRS
CUSIP03236M10
Phone510-450-0761

Debt

Debt-to-Equity Ratio-0.24
Current Ratio0.42
Quick Ratio0.38

Price-To-Earnings

Trailing P/E Ratio-2.47
Forward P/E Ratio-5.26
P/E GrowthN/A

Sales & Book Value

Annual Sales$143.45 million
Price / Sales3.36
Cash FlowN/A
Price / CashN/A
Book Value($4.64) per share
Price / Book-1.62

Profitability

EPS (Most Recent Fiscal Year)($3.05)
Net Income$-72,320,000.00
Net Margins-84.53%
Return on EquityN/A
Return on Assets-97.93%

Miscellaneous

Employees414
Outstanding Shares64,050,000
Market Cap$482.92 million

Amyris (NASDAQ:AMRS) Frequently Asked Questions

What is Amyris' stock symbol?

Amyris trades on the NASDAQ under the ticker symbol "AMRS."

When did Amyris' stock split? How did Amyris' stock split work?

Shares of Amyris reverse split on the morning of Tuesday, June 6th 2017. The 1-15 reverse split was announced on Tuesday, June 6th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Monday, June 5th 2017. An investor that had 100 shares of Amyris stock prior to the reverse split would have 7 shares after the split.

How were Amyris' earnings last quarter?

Amyris Inc (NASDAQ:AMRS) announced its quarterly earnings data on Monday, August, 6th. The biotechnology company reported ($0.38) earnings per share for the quarter, missing the consensus estimate of ($0.30) by $0.08. The biotechnology company earned $24.81 million during the quarter, compared to analysts' expectations of $37.52 million. The business's revenue was down 3.4% on a year-over-year basis. During the same period last year, the company posted ($1.32) EPS. View Amyris' Earnings History.

When is Amyris' next earnings date?

Amyris is scheduled to release their next quarterly earnings announcement on Tuesday, November 13th 2018. View Earnings Estimates for Amyris.

What price target have analysts set for AMRS?

3 equities research analysts have issued 12 month price targets for Amyris' stock. Their forecasts range from $4.00 to $15.00. On average, they anticipate Amyris' share price to reach $9.6667 in the next year. This suggests a possible upside of 28.7% from the stock's current price. View Analyst Price Targets for Amyris.

What is the consensus analysts' recommendation for Amyris?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amyris in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Amyris.

What are Wall Street analysts saying about Amyris stock?

Here are some recent quotes from research analysts about Amyris stock:
  • 1. According to Zacks Investment Research, "Amyris INC is an integrated renewable products company applying industrial synthetic biology to genetically modify microorganisms to serve as living factories. Amyris designs these microorganisms to produce defined molecules for use as renewable chemicals and transportation fuels. The Company is engaged in the development of farmesene- a molecule, which serves as the base chemical building block for a wide range of renewable products to replace existing products that are derived from petroleum, plant or animal sources and that may be of lower quality or higher price. Amyris INC is headquartered in Emeryville, CA. " (10/9/2018)
  • 2. HC Wainwright analysts commented, "We expect the company’s topline to grow at a five-year CAGR of 30.7% from $185.9M in 2018 to $715.6M in 2023. We expect mid- to long-term gross margins to fluctuate between 60-70%, driven by lumpiness of the high margin revenues from grants and collaboration. We are projecting operating expenses to grow at a five-year CAGR of 7.4% from 2018 to 2023. We expect the company to achieve EBITDA profitability during 2018. Based on these assumptions, we arrive at a valuation of $15.00 per share for AMRS stock." (9/28/2018)

Who are some of Amyris' key competitors?

Who are Amyris' key executives?

Amyris' management team includes the folowing people:
  • Mr. John G. Melo, Pres, CEO & Director (Age 52)
  • Ms. Kathleen Valiasek, Chief Financial Officer (Age 54)
  • Mr. Eduardo Alvarez, Chief Operating Officer (Age 54)
  • Ms. Nicole Kelsey, Gen. Counsel & Sec. (Age 51)
  • Dr. Joel R. Cherry, Pres of R&D (Age 57)

Who are Amyris' major shareholders?

Amyris' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Bank of Montreal Can (0.04%) and Fox Run Management L.L.C. (0.02%). Company insiders that own Amyris stock include (Mauritius) Pte Ltd Maxwell, Eduardo Alvarez, Frank Kung, John Melo, Kathleen Valiasek, L John Doerr and Patrick Y Yang. View Institutional Ownership Trends for Amyris.

Which institutional investors are buying Amyris stock?

AMRS stock was acquired by a variety of institutional investors in the last quarter, including Bank of Montreal Can and Fox Run Management L.L.C.. Company insiders that have bought Amyris stock in the last two years include Eduardo Alvarez, Kathleen Valiasek and Patrick Y Yang. View Insider Buying and Selling for Amyris.

How do I buy shares of Amyris?

Shares of AMRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Amyris' stock price today?

One share of AMRS stock can currently be purchased for approximately $7.51.

How big of a company is Amyris?

Amyris has a market capitalization of $482.92 million and generates $143.45 million in revenue each year. The biotechnology company earns $-72,320,000.00 in net income (profit) each year or ($3.05) on an earnings per share basis. Amyris employs 414 workers across the globe.

What is Amyris' official website?

The official website for Amyris is http://www.amyris.com.

How can I contact Amyris?

Amyris' mailing address is 5885 HOLLIS STREET SUITE 100, EMERYVILLE CA, 94608. The biotechnology company can be reached via phone at 510-450-0761 or via email at [email protected]


MarketBeat Community Rating for Amyris (NASDAQ AMRS)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  225 (Vote Outperform)
Underperform Votes:  285 (Vote Underperform)
Total Votes:  510
MarketBeat's community ratings are surveys of what our community members think about Amyris and other stocks. Vote "Outperform" if you believe AMRS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AMRS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/22/2018 by MarketBeat.com Staff

Featured Article: The risks of owning bonds

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel